Pipelines

(Image: Getty/Bong Hyunjung)

MedImmune will cease to exist after 30 years

By Ben Hargreaves

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

(Image: Getty/	SCIEPRO/SCIENCE PHOTO LIBRARY)

CAR-T for solid tumors drives industry to innovate

By Maggie Lynch

ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.

Follow us

Products

View more

Webinars